EUVIMEDObjevte EUVIMED
Multizentrische StudieVergleichsstudie

Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study

Takafumi Yanagisawa iD, Wataru Fukuokaya iD, Shingo Hatakeyama, Shintaro Narita iD, Katsuki Muramoto, Kouta Katsumi, Hidetsugu Takahashi, Fumihiko Urabe iD, Keiichiro Mori, Kojiro Tashiro, Kosuke Iwatani, Tatsuya Shimomura and 2 more

The Prostate · 2025

DOI: 10.1002/pros.24813 ↗

At a glance

Multizentrische Studie in The Prostate, 2025. Written by Takafumi Yanagisawa and 13 co-authors. Institution: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Major MEDLINE topics: Androstenes, Benzamides, Nitriles, Phenylthiohydantoin. Cited 24 times so far (Crossref); 34 references. Funded by: Mochida Pharmaceutical Company, Sysmex Corporation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

We aimed to assess the differential efficacy and safety of androgen receptor pathway inhibitors (ARPI), such as abiraterone, enzalutamide, and apalutamide, in patients with metastatic hormone‐sensitive prostate cancer (mHSPC) in a real‐world practice setting.

Methods

We retrospectively reviewed the records of consequent 668 patients with mHSPC treated with ARPI plus androgen deprivation therapy between September 2015 and December 2023. Based on the LATITUDE criteria, the comparison among abiraterone, enzalutamide, and apalutamide was exclusively conducted in high‐risk patients. Prostate‐specific antigen (PSA) responses such as the achievement of 95% and 99% PSA decline, overall survival (OS), cancer‐specific survival (CSS), time to castration‐resistant prostate cancer (CRPC), and the incidence of adverse events (AEs) were compared. All two‐group comparisons relied on propensity score matching (PSM) to minimize the effect on possible confounders.

Results

In total, 297 patients with high‐risk mHSPC treated with abiraterone, 127 with enzalutamide, and 142 with apalutamide were compared. There were no differences in time to CRPC ( p = 0.13), OS ( p = 0.7), and CSS ( p = 0.5) among the three ARPIs. No differences were observed in the achievement rates for 95% PSA decline at 3 months among the three ARPIs, while abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). The aforementioned oncologic outcomes were sustained even when performing PSM analyzes. Although skin rash for APA (34%) was the highest incidence of AEs, there were no differences in the rates of severe AEs across the three ARPIs. Enzalutamide resulted in the lowest treatment discontinuation rates (10%) other than disease progression compared to the other regimens.

Conclusions

Abiraterone, enzalutamide, and apalutamide have comparable oncologic outcomes in terms of OS, CSS, and time to CRPC in patients with high‐risk mHSPC. Our data on differential treatment discontinuation rates, PSA response, and AE profiles can help guide clinical decision‐making.

Subjects

MeSH terms (MEDLINE)

AndrostenesBenzamidesNitrilesPhenylthiohydantoinThiohydantoinsAgedAged, 80 and overHumansMaleMiddle AgedAndrogen Receptor AntagonistsProstate-Specific AntigenProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRetrospective StudiesTreatment Outcome

Author keywords

abirateroneandrogen receptor pathway inhibitorsapalutamideenzalutamidemetastatic hormone‐sensitive prostate cancer

Substances

abirateroneAndrogen Receptor AntagonistsAndrostenesapalutamideBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific AntigenThiohydantoins

Authors and institutions

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Division of Advanced Blood Purification Therapy, Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Department of Urology, Akita University School of Medicine, Akita, Japan.

ORCID profiles: Takafumi Yanagisawa, Wataru Fukuokaya, Shintaro Narita, Fumihiko Urabe

Funding

  • Mochida Pharmaceutical Company
  • Sysmex Corporation

Cite

APA

Yanagisawa, T., Fukuokaya, W., Hatakeyama, S., Narita, S., Muramoto, K., Katsumi, K., Takahashi, H., Urabe, F., Mori, K., Tashiro, K., Iwatani, K., Shimomura, T., Habuchi, T., & Kimura, T. (2025). Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study. The Prostate. https://doi.org/10.1002/pros.24813

Vancouver

Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, et al. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study. The Prostate. 2025. doi:10.1002/pros.24813

BibTeX
@article{Yanagisawa2025,
  author = {Yanagisawa, Takafumi and Fukuokaya, Wataru and Hatakeyama, Shingo and Narita, Shintaro and Muramoto, Katsuki and Katsumi, Kouta and Takahashi, Hidetsugu and Urabe, Fumihiko and Mori, Keiichiro and Tashiro, Kojiro and Iwatani, Kosuke and Shimomura, Tatsuya and Habuchi, Tomonori and Kimura, Takahiro},
  title = {Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24813}
}
Start for free →